Precigen ActoBio, announced additional positive interim data from the ongoing Phase 1b/2a clinical study investigating AG019 ActoBiotics™ for the treatment of recent-onset type 1 diabetes.
[Precigen ActoBio]
6445212
nan
items
1
apa
0
default
asc
1
167483
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
